Laverock Therapeutics secures £1m funding via the Innovate UK Investor Partnerships Future Economy programme, supported by UKI2S. London, UK, 30th October 2023 / Sciad Newswire / Laverock Therapeutics, developer of a unique gene silencing platform for the creation of programmable advanced therapies, is pleased to an.
Laverock Therapeutics, the gene editing-induced gene silencing platform for human therapeutic applications, has expanded its seed funding round to £13.5 million.